IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Efficacy and Safety of Etoricoxib in Acute Ankle Sprain: A Double-Blind Comparative Study Among 2 Treatments Protocols
The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2008 by Núcleo de Estudos em Esportes e Ortopedia, Brazil.
Recruitment status was: Not yet recruiting
Recruitment status was: Not yet recruiting
Sponsor:
Núcleo de Estudos em Esportes e Ortopedia, Brazil
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by:
Núcleo de Estudos em Esportes e Ortopedia, Brazil
ClinicalTrials.gov Identifier:
NCT00525993
First received: September 4, 2007
Last updated: October 20, 2008
Last verified: October 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The investigators will study 2 doses of etoricoxib to prove that 60 mg once daily will be non-inferior to etoricoxib 90mg daily (for 14 days) in the treatment of acute ankle sprain in sports. The investigators objective is to discuss the point that the investigators will follow the minimal dose that is effective for the treatment of this acute condition in orthopedic.
| Condition | Intervention | Phase |
|---|---|---|
| Sprains and Strains Contusions | Drug: etoricoxib 90mg 14 days Drug: etoricoxib 60mg daily for 14 days | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Efficacy and Safety of the Non-Steroidal Anti-Inflammatory Drug Etoricoxib in the Treatment of Acute Ankle Sprain in Sports: A Randomized Double-Blind Comparative Study Among 2 Treatments in the Acute Phase |
Further study details as provided by Núcleo de Estudos em Esportes e Ortopedia, Brazil:
Primary Outcome Measures:
- Reduction of pain during active mobilization measured using a visual analogue scale VAS at day 8 [ Time Frame: 8 days ]
- Volumetric measurement of the ankle and foot [ Time Frame: day 1 and day 8 ]
Secondary Outcome Measures:
- Pain during motion against resistance [ Time Frame: day 15 ]
- Functional impairment and global assessment of efficacy by either patient and investigator [ Time Frame: day 15 ]
- Tolerability will be assessed by the frequency of adverse experiences and global assessment of efficacy by either patient and investigator [ Time Frame: day 15 ]
| Estimated Enrollment: | 50 |
| Study Start Date: | December 2008 |
| Estimated Study Completion Date: | September 2009 |
| Estimated Primary Completion Date: | August 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: A |
Drug: etoricoxib 60mg daily for 14 days
Patients in this group will receive 60mg of the drug, daily
|
| Active Comparator: B |
Drug: etoricoxib 90mg 14 days
each patient in this group will receive 90mg once daily, for the 14 days treatment.
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- patients that suffered an ankle sprain in the last 12 hours and seek medical assistance
Exclusion Criteria:
- anterior history of trauma / fractures in the affected ankle
- history of hypertension / gastrointestinal problems
- patients that did not agree to sign the informed consent to participate in the study
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00525993
Please refer to this study by its ClinicalTrials.gov identifier: NCT00525993
Contacts
| Contact: Rogerio T Silva, MD, PhD | 55.11.81716767 | rgtsilva@uol.com.br | |
| Contact: Adriana N Greggio | 55.11.55495581 | adi.adi@terra.com.br |
Locations
| Brazil | |
| NEO | Not yet recruiting |
| São Paulo, SP, Brazil, 04084100 | |
| Contact: Rogerio Silva 011 81716767 rgtsilva@uol.com.br | |
| Principal Investigator: Rogerio T Silva, MD, PhD | |
| Sub-Investigator: Fabio C Petri, MD | |
Sponsors and Collaborators
Núcleo de Estudos em Esportes e Ortopedia, Brazil
Merck Sharp & Dohme Corp.
Investigators
| Principal Investigator: | Rogerio T Silva, MD, PhD | NEO - Orthopedic Sports Medicine Research Center |
| Study Director: | Lidia F Souza, PT | NEO - Orthopedic Sports Medicine Research Center |
| Study Director: | Cristiano FS Laurino, MD | NEO - Orthopedic Sports Medicine Research Center |
More Information
| Responsible Party: | Rogerio Teixeira da Silva, NEO - Núcleo de Estudos em Esportes e Ortopedia |
| ClinicalTrials.gov Identifier: | NCT00525993 History of Changes |
| Other Study ID Numbers: |
NeoBrazil_EtoricoxibAnkle2007 |
| Study First Received: | September 4, 2007 |
| Last Updated: | October 20, 2008 |
Keywords provided by Núcleo de Estudos em Esportes e Ortopedia, Brazil:
|
sports ankle sprain |
etoricoxib antiinflammatory treatment outcome |
Additional relevant MeSH terms:
|
Sprains and Strains Ankle Injuries Contusions Wounds and Injuries Leg Injuries Wounds, Nonpenetrating Etoricoxib Anti-Inflammatory Agents, Non-Steroidal Cyclooxygenase 2 Inhibitors Cyclooxygenase Inhibitors |
Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents |
ClinicalTrials.gov processed this record on July 21, 2017